SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (3209)12/8/1997 8:33:00 AM
From: Peter Singleton  Read Replies (1) of 6136
 
Miljenko,

Thanks for carefully walking through the VX-478 PII data. Very helpful.

I hope this clears up for the AGPH bulls (myself being one) the board the importance of unpacking dose-ranging PII data. It's also important to remember this is BID data, as far as I know with or without food. An easier dosing regimen than any of the currently marketed PIs (at least for now).

Also, thanks for addressing the patient drop out issue on the 1200mg dose. The fact that VRTX is going forward w/ 1200mg and the later trials have seen much lower drop outs indicates this is a well-tolerated dose.

I haven't heard anything other than unsubstantiated assertions that would change my assumption that VX-478 should be a very strong market entry.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News